2022-05-2 - Cancer Synoptic Reporting Project Group Meeting

Dear Scott,

thinking about yesterdays discussion, it might be wise to think of a genetic abnormality hierarchy:

Many of the acute leukemias are now defined by genetic change and these categories have a range of morphology according to the FAB classification.

In the bone marrow diseases you will find hairy cell leukemia wich has a subtype of BRAF V600E mutated hairy cell leukemia.

However BRAF V600E (and variants) mutation is the driver for many other neoplasms of different lineages (melanoma, papillary thyroid carcinoma, ameloblastoma).

The same ist true for may other mutations (KRAS, EGFR, BRACA) and in times of precision oncology these drive the therapeutic possibilities

The morphologic differences of mutated vs. unmutated tumors are not yet understood in most cases.

Therefore, it might be feasible to have an independent genetic hierarchy that can also be used to model disorders. (In addition in records it might be needed to use a string for so far unclassified mutations.)

Hairy cell leukemia is also a good example for a disorder now defined genetically. Cases that lack the BRAV V600E mutation are now separated out as splenic B-cell lymphoma/ leukemia, unclassifiable, a subgroup of which is variant hairy cell leukemia. Still the WHO-"FSN" remains hairy cell leukemia.

Hi Scott, 

I am not sure, whether I understand everything correctly:

I think having a possibility to infer all disorders with a certain genetic change (or respective patients) has value: You could identify everybody suitable for a new targeted therapy (some exceptions exist).

I think, we should have a possibility to define the genetic abnormality independent from morphology. In genetically defined leukemias in the WHO classification, morphology may  according to FAB classification may vary. However if there is a question of recurrence, you still use morphology for the first report, so it might be good to have the possibility to address morphology and genetic change independent from each other (at least in a record). CNS bluebook for astrocytic neoplasms now distinguishes between NOS (genteic abnormality not investigated), IDH1 mutated and unmutated, always in triples. However, IDH1 mutations may also be detected in intrahepatic cholangiocarcinoma.

Perhaps you can persuade Jim Case to extend the disorder concept model to include genetic change?